Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) SVP C Frank Bennett sold 11,200 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $36.78, for a total value of $411,936.00. Following the completion of the sale, the senior vice president now directly owns 4,336 shares of the company’s stock, valued at approximately $159,478. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $41.10.

ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 0.36% during mid-day trading on Wednesday, hitting $36.10. The stock had a trading volume of 2,025,060 shares. ISIS Pharmaceuticals has a one year low of $22.25 and a one year high of $62.66. The stock’s 50-day moving average is $29.47 and its 200-day moving average is $39.85. The company’s market cap is $4.245 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter last year, the company posted ($0.02) earnings per share. ISIS Pharmaceuticals’s revenue was down 35.0% compared to the same quarter last year. Analysts expect that ISIS Pharmaceuticals will post $-0.71 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.